News articles about LeMaitre Vascular (NASDAQ:LMAT) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. LeMaitre Vascular earned a news impact score of 0.01 on Accern’s scale. Accern also gave media coverage about the medical instruments supplier an impact score of 96 out of 100, indicating that recent media coverage is extremely likely to have an effect on the stock’s share price in the near future.
These are some of the headlines that may have effected Accern Sentiment’s scoring:
- ETFs with exposure to LeMaitre Vascular, Inc. : July 14, 2017 (finance.yahoo.com)
- The Brokerages Expect LeMaitre Vascular, Inc (fumbleboard.com)
- LeMaitre Vascular Will Announce Second Quarter 2017 Earnings Results on July 27, 2017 (finance.yahoo.com)
- LeMaitre Vascular, Inc. breached its 50 day moving average in a Bearish Manner : LMAT-US : July 11, 2017 (finance.yahoo.com)
- BUZZ-LeMaitre Vascular Inc: Set for worst day since 2009 (timesofindia.indiatimes.com)
Shares of LeMaitre Vascular (LMAT) traded up 0.31% on Friday, reaching $29.14. The company had a trading volume of 179,169 shares. The company has a market capitalization of $548.09 million, a PE ratio of 48.65 and a beta of 0.63. The company’s 50-day moving average is $30.02 and its 200-day moving average is $25.94. LeMaitre Vascular has a one year low of $13.52 and a one year high of $33.22.
LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, May 4th. The medical instruments supplier reported $0.16 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.03. The business had revenue of $24.10 million during the quarter, compared to the consensus estimate of $23.48 million. LeMaitre Vascular had a net margin of 12.52% and a return on equity of 13.36%. LeMaitre Vascular’s quarterly revenue was up 18.7% compared to the same quarter last year. Equities research analysts predict that LeMaitre Vascular will post $0.70 earnings per share for the current year.
A number of research analysts have recently commented on the company. Zacks Investment Research upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $36.00 price target for the company in a research note on Friday, April 28th. Canaccord Genuity reaffirmed a “buy” rating and set a $28.00 target price on shares of LeMaitre Vascular in a research report on Thursday, April 27th. Craig Hallum started coverage on LeMaitre Vascular in a research report on Tuesday, June 6th. They set a “hold” rating and a $31.00 target price for the company. Stifel Nicolaus raised their target price on LeMaitre Vascular from $25.00 to $29.00 and gave the stock a “buy” rating in a research report on Friday, April 28th. Finally, Benchmark Co. lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Monday, July 10th. They noted that the move was a valuation call. Six research analysts have rated the stock with a hold rating and three have given a buy rating to the company. LeMaitre Vascular has a consensus rating of “Hold” and an average price target of $27.00.
ILLEGAL ACTIVITY NOTICE: “LeMaitre Vascular (LMAT) Getting Somewhat Positive News Coverage, Analysis Finds” was reported by BBNS and is owned by of BBNS. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://baseballnewssource.com/markets/lemaitre-vascular-lmat-getting-somewhat-positive-news-coverage-analysis-finds/1204155.html.
In other LeMaitre Vascular news, CEO George W. Lemaitre sold 9,102 shares of the business’s stock in a transaction on Monday, May 8th. The shares were sold at an average price of $31.12, for a total value of $283,254.24. Following the completion of the sale, the chief executive officer now directly owns 3,450,815 shares of the company’s stock, valued at $107,389,362.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Trent G. Kamke sold 15,780 shares of the business’s stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $30.28, for a total transaction of $477,818.40. Following the completion of the sale, the insider now directly owns 31,341 shares of the company’s stock, valued at $949,005.48. The disclosure for this sale can be found here. Insiders sold 317,805 shares of company stock valued at $9,910,332 over the last three months. 23.70% of the stock is currently owned by insiders.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with our FREE daily email newsletter.